Argenx Releases New Clinical Data for Efgartigimod in Myositis and Sjogren's Disease
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: NASDAQ.COM
- Clinical Trial Progress: In Argenx's Phase 2 extension studies for efgartigimod targeting myositis and Sjogren's disease, 37.5% of myositis patients achieved a significant 75% improvement in TIS at 52 weeks, demonstrating the drug's potential in treating chronic autoimmune diseases.
- Safety Assessment: Efgartigimod exhibited a favorable safety and tolerability profile across 834 tested patients, supporting its application in myositis, Sjogren's disease, and lupus nephritis, thereby enhancing market confidence in its future development.
- Efficacy Sustainability: In the RHO+ trial, patients receiving efgartigimod recorded a median ClinESSDAI of 2.5 at week 72, indicating sustained clinical response and further validating the drug's effectiveness in treating Sjogren's disease.
- Future Outlook: The ongoing Phase 3 UNITY trial is expected to release topline data in the second half of 2027, and positive results could lay the groundwork for efgartigimod's market introduction in Sjogren's disease.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARGX
Wall Street analysts forecast ARGX stock price to rise
17 Analyst Rating
14 Buy
3 Hold
0 Sell
Strong Buy
Current: 862.180
Low
858.00
Averages
1048
High
1317
Current: 862.180
Low
858.00
Averages
1048
High
1317
About ARGX
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Argenx Releases New Clinical Data for Efgartigimod in Myositis and Sjogren's Disease
- Clinical Trial Progress: In Argenx's Phase 2 extension studies for efgartigimod targeting myositis and Sjogren's disease, 37.5% of myositis patients achieved a significant 75% improvement in TIS at 52 weeks, demonstrating the drug's potential in treating chronic autoimmune diseases.
- Safety Assessment: Efgartigimod exhibited a favorable safety and tolerability profile across 834 tested patients, supporting its application in myositis, Sjogren's disease, and lupus nephritis, thereby enhancing market confidence in its future development.
- Efficacy Sustainability: In the RHO+ trial, patients receiving efgartigimod recorded a median ClinESSDAI of 2.5 at week 72, indicating sustained clinical response and further validating the drug's effectiveness in treating Sjogren's disease.
- Future Outlook: The ongoing Phase 3 UNITY trial is expected to release topline data in the second half of 2027, and positive results could lay the groundwork for efgartigimod's market introduction in Sjogren's disease.
See More
argenx Presents New Efgartigimod Data at EULAR 2026
- Significant Clinical Improvement: In the ALKIVIA+ study, 37.5% of patients continuously receiving efgartigimod maintained a major Total Improvement Score (TIS) ≥60 at 52 weeks, indicating the long-term efficacy of efgartigimod in myositis patients, potentially providing sustained functional improvement and alleviating disease burden.
- Consistent Safety Profile: Efgartigimod demonstrated a consistent safety profile across multiple autoimmune rheumatic disease studies, with 834 patients followed for over 1,300 patient-years, showing no new safety signals, which enhances its market competitiveness and long-term viability.
- Response Maintenance in Sjogren's Disease: In the RHO+ study, patients receiving efgartigimod maintained good clinical responses after switching to biweekly dosing, with ClinESSDAI scores below 5 at week 72, demonstrating the efficacy and safety of efgartigimod in Sjogren's disease patients.
- Future Research Outlook: Argenx plans to announce topline results from the ALKIVIA study in Q3 2026 and from the UNITY study in the second half of 2027, further validating the potential of efgartigimod across various autoimmune diseases, which may drive future growth for the company.
See More
argenx Hosts Webinar on Advancing FcRn Leadership in Autoimmune Myositis
- Webinar Announcement: argenx will host a webinar titled 'R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis' on June 23, 2026, at 2:00 PM ET, aimed at exploring the research and development strategy for autoimmune myositis.
- Disease Biology Insights: The webinar will feature discussions by the argenx team and leading clinicians on emerging insights into disease biology, particularly the role of autoantibodies as key drivers of disease progression, providing critical theoretical support for clinical research.
- ALKIVIA Clinical Program: The event will also cover the design of the ALKIVIA clinical program and its clinical and commercial opportunities for efgartigimod, emphasizing the drug's potential in treating severe autoimmune diseases.
- Investor Access: The live webcast will be available on the investors section of the argenx website, with a replay accessible for approximately one year, ensuring investors can stay informed about relevant developments.
See More
argenx Management to Attend Investor Conferences in June
- Investor Conference Schedule: argenx's management team will participate in two significant investor conferences in June 2026, namely the William Blair 46th Annual Growth Stock Conference and the Goldman Sachs 47th Annual Global Healthcare Conference, showcasing the company's strategic positioning and growth potential in its field.
- Conference Timing and Location: At the William Blair conference, management will present on June 3 at 12:40 p.m. CT in Chicago, while at the Goldman Sachs conference, they will engage in a fireside chat on June 9 at 4:00 p.m. ET, enhancing interaction with investors.
- Live Webcast and Replay: The presentation will be live-streamed on the investors section of the argenx website, and a replay will be available for approximately 30 days post-presentation, ensuring that investors who cannot attend live can access the information, thereby increasing company transparency.
- Company Background: argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, developing and commercializing the first approved neonatal Fc receptor blocker, demonstrating broad potential in multiple serious autoimmune diseases, which reflects its strategic advantage in innovative drug development.
See More
MindWalk Reports Significant Progress in Drug Development
- Clinical Trial Count: MindWalk's antibody discovery efforts have led to over 20 partner-owned drug programs entering clinical trials, with ten currently in active Phase 1-3 trials, showcasing the company's robust R&D capabilities in biopharmaceuticals.
- Establishing Scientific Standards: With over 400 peer-reviewed publications and patents, MindWalk has established a rare scientific standard in the industry, ensuring a consistent output of clinical-stage assets across multiple therapeutic areas for its partners.
- Biological Intelligence Infrastructure: The HYFT® system and LensAI™ platform, developed as a purpose-built AI architecture, integrate biological pattern recognition technology, enhancing the efficiency and success rate of clinical asset development within MindWalk's antibody discovery engine.
- Strategic Partnerships: MindWalk collaborates with several prominent biopharmaceutical companies, including Annexon Biosciences and argenx, further solidifying its market position and influence in the biopharmaceutical industry.
See More
argenx SE Receives FDA Approval for VYVGART Label Expansion
- FDA Label Expansion: The U.S. FDA has approved VYVGART and VYVGART Hytrulo for all adult generalized myasthenia gravis (gMG) patients, covering all antibody subtypes, marking a significant advancement in treatment options.
- Clinical Trial Results: In the ADAPT SERON study, patients treated with VYVGART showed statistically significant improvements, with a 3.35-point enhancement in MG-ADL total score at week 4, demonstrating the treatment's effectiveness and sustainability.
- Significant Sales Growth: Argenx reported $1.3 billion in global net sales for the VYVGART franchise in Q1 2026, reflecting a 63% year-over-year increase, indicating strong market demand and product acceptance.
- Broad Market Potential: This approval positions VYVGART as the first treatment available for all gMG patients, expected to further drive sales growth and solidify the company's market position in the rare disease sector.
See More
Argenx Releases New Clinical Data for Efgartigimod in Myositis and Sjogren's Disease
- Clinical Trial Progress: In Argenx's Phase 2 extension studies for efgartigimod targeting myositis and Sjogren's disease, 37.5% of myositis patients achieved a significant 75% improvement in TIS at 52 weeks, demonstrating the drug's potential in treating chronic autoimmune diseases.
- Safety Assessment: Efgartigimod exhibited a favorable safety and tolerability profile across 834 tested patients, supporting its application in myositis, Sjogren's disease, and lupus nephritis, thereby enhancing market confidence in its future development.
- Efficacy Sustainability: In the RHO+ trial, patients receiving efgartigimod recorded a median ClinESSDAI of 2.5 at week 72, indicating sustained clinical response and further validating the drug's effectiveness in treating Sjogren's disease.
- Future Outlook: The ongoing Phase 3 UNITY trial is expected to release topline data in the second half of 2027, and positive results could lay the groundwork for efgartigimod's market introduction in Sjogren's disease.
See More
argenx Presents New Efgartigimod Data at EULAR 2026
- Significant Clinical Improvement: In the ALKIVIA+ study, 37.5% of patients continuously receiving efgartigimod maintained a major Total Improvement Score (TIS) ≥60 at 52 weeks, indicating the long-term efficacy of efgartigimod in myositis patients, potentially providing sustained functional improvement and alleviating disease burden.
- Consistent Safety Profile: Efgartigimod demonstrated a consistent safety profile across multiple autoimmune rheumatic disease studies, with 834 patients followed for over 1,300 patient-years, showing no new safety signals, which enhances its market competitiveness and long-term viability.
- Response Maintenance in Sjogren's Disease: In the RHO+ study, patients receiving efgartigimod maintained good clinical responses after switching to biweekly dosing, with ClinESSDAI scores below 5 at week 72, demonstrating the efficacy and safety of efgartigimod in Sjogren's disease patients.
- Future Research Outlook: Argenx plans to announce topline results from the ALKIVIA study in Q3 2026 and from the UNITY study in the second half of 2027, further validating the potential of efgartigimod across various autoimmune diseases, which may drive future growth for the company.
See More
argenx Hosts Webinar on Advancing FcRn Leadership in Autoimmune Myositis
- Webinar Announcement: argenx will host a webinar titled 'R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis' on June 23, 2026, at 2:00 PM ET, aimed at exploring the research and development strategy for autoimmune myositis.
- Disease Biology Insights: The webinar will feature discussions by the argenx team and leading clinicians on emerging insights into disease biology, particularly the role of autoantibodies as key drivers of disease progression, providing critical theoretical support for clinical research.
- ALKIVIA Clinical Program: The event will also cover the design of the ALKIVIA clinical program and its clinical and commercial opportunities for efgartigimod, emphasizing the drug's potential in treating severe autoimmune diseases.
- Investor Access: The live webcast will be available on the investors section of the argenx website, with a replay accessible for approximately one year, ensuring investors can stay informed about relevant developments.
See More
argenx Management to Attend Investor Conferences in June
- Investor Conference Schedule: argenx's management team will participate in two significant investor conferences in June 2026, namely the William Blair 46th Annual Growth Stock Conference and the Goldman Sachs 47th Annual Global Healthcare Conference, showcasing the company's strategic positioning and growth potential in its field.
- Conference Timing and Location: At the William Blair conference, management will present on June 3 at 12:40 p.m. CT in Chicago, while at the Goldman Sachs conference, they will engage in a fireside chat on June 9 at 4:00 p.m. ET, enhancing interaction with investors.
- Live Webcast and Replay: The presentation will be live-streamed on the investors section of the argenx website, and a replay will be available for approximately 30 days post-presentation, ensuring that investors who cannot attend live can access the information, thereby increasing company transparency.
- Company Background: argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, developing and commercializing the first approved neonatal Fc receptor blocker, demonstrating broad potential in multiple serious autoimmune diseases, which reflects its strategic advantage in innovative drug development.
See More
MindWalk Reports Significant Progress in Drug Development
- Clinical Trial Count: MindWalk's antibody discovery efforts have led to over 20 partner-owned drug programs entering clinical trials, with ten currently in active Phase 1-3 trials, showcasing the company's robust R&D capabilities in biopharmaceuticals.
- Establishing Scientific Standards: With over 400 peer-reviewed publications and patents, MindWalk has established a rare scientific standard in the industry, ensuring a consistent output of clinical-stage assets across multiple therapeutic areas for its partners.
- Biological Intelligence Infrastructure: The HYFT® system and LensAI™ platform, developed as a purpose-built AI architecture, integrate biological pattern recognition technology, enhancing the efficiency and success rate of clinical asset development within MindWalk's antibody discovery engine.
- Strategic Partnerships: MindWalk collaborates with several prominent biopharmaceutical companies, including Annexon Biosciences and argenx, further solidifying its market position and influence in the biopharmaceutical industry.
See More
argenx SE Receives FDA Approval for VYVGART Label Expansion
- FDA Label Expansion: The U.S. FDA has approved VYVGART and VYVGART Hytrulo for all adult generalized myasthenia gravis (gMG) patients, covering all antibody subtypes, marking a significant advancement in treatment options.
- Clinical Trial Results: In the ADAPT SERON study, patients treated with VYVGART showed statistically significant improvements, with a 3.35-point enhancement in MG-ADL total score at week 4, demonstrating the treatment's effectiveness and sustainability.
- Significant Sales Growth: Argenx reported $1.3 billion in global net sales for the VYVGART franchise in Q1 2026, reflecting a 63% year-over-year increase, indicating strong market demand and product acceptance.
- Broad Market Potential: This approval positions VYVGART as the first treatment available for all gMG patients, expected to further drive sales growth and solidify the company's market position in the rare disease sector.
See More
